RxDoctor Payments DataLook up a doctor →

Scott Sheftel

Dermatology · Tucson, AZNPI 1134128564

Payments from drug & device makers

$11,198in general payments, 2019–2025

Across 421 payments — averaging $26.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Theragenics Corporation$2K
  • Sanofi$2K
  • AbbVie$2K
  • Johnson & Johnson$1K
  • LEO Pharma Inc.$590
  • Regeneron Healthcare Solutions, Inc.$571
  • plus $3K from 26 others

What the payments were for

  • Consulting fees$3,86935%
  • Food & beverage$7,26265%
  • Education$671%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,198 in reported general payments places this provider in the 80th percentile of 305 dermatology providers in Arizona.

See all dermatology providers in Arizona

Medicare billing

Part B allowed, 2024
$999,944
Medicare patients
3,664
Services billed
18,437

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib15$96,882
Dupixent SyringeDupilumab17$71,804
Dupixent PenDupilumab13$48,823
Fluorouracil149$9,146
Betamethasone Dipropionate79$3,289
Triamcinolone Acetonide227$2,828
Ketoconazole162$2,650
Clobetasol Propionate53$2,522
Doxycycline Hyclate81$2,172
Hydrocortisone76$1,489
Metronidazole29$1,380
Mometasone Furoate56$1,187
ValacyclovirValacyclovir Hcl82$1,047
Fluocinonide27$816
Imiquimod35$677

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$1,671$96,88215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 305 dermatology providers in Arizona.

Other dermatology in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →